Melissa Harting receives the shot
New York nurse Melissa Harting receives a shot during the Moderna phase 3 trial
Photo: AP
Prof. Tal Zaks, Moderna's chief medical officer

'Israel to receive Moderna COVID vaccine as soon as its ready'

Biotech company's Israeli chief medical officer tells Ynet that, 'Israeli government has indeed seen fit to make sure vaccination will be available to population'; says results of final phase of clinical trial involving 30,000 people expected by year's end

Atilla Somfalvi, Associated Press |
Published: 08.01.20 , 13:40
Israel's government is working to ensure that its citizens can receive Moderna's COVID-19 vaccine as soon as it is ready, says the company's Israeli Chief Medical Officer, Prof. Tal Zaks.
  • Follow Ynetnews on Facebook and Twitter

  • The American biotechnology company, working together with the National Institutes of Health in the U.S., has recently begun the third and final stage of the clinical trial of the vaccination.
    טל זקס מודרנה חיסוןטל זקס מודרנה חיסון
    Prof. Tal Zaks, Moderna's chief medical officer
    (Photo: Courtesy)
    "As a former Israeli I'm glad to know that the Israeli government has indeed seen fit to make sure the vaccination will be available to its population," Zaks, who started his career at Ben-Gurion University in the Negev, told Ynet this week.
    Zaks said he could not share specifics on the countries that have already ordered the vaccine but did confirm that Israel is among them.
    Moderna and the National Institutes of Health are starting mass human trials with 30,000 participants - half will receive the vaccination and the other half a placebo.
    חיסון מודרנהחיסון מודרנה
    Moderna COVID-19 vaccination trial
    (Photo: AP)
    If successful, the trial that is supposed to end in October will dramatically decrease the chances of contracting the virus for those who have received the true vaccinations
    "People are receiving the vaccination as we speak," Zaks told Ynet.
    "The participants will receive one dose of the vaccination now and another in four weeks. In the first phase of the trial, we saw that the second dose can boost one's antibodies to even higher levels than those who have contracted the coronavirus in the past."
    According to Zaks, the third phase of the trial is meant to prove that the experimental vaccination can prevent contracting the disease altogether.
    "Since the current phase includes a rather large control group, we will be able to determine how effective the vaccination really is," he said.
    He said the subjects involved in the trial are supposed to represent the make-up of the American public.
    "[It is] mainly those over 18, with at least a quarter of the participants being over 65 or having underlying illnesses," he said.
    "Beyond that, the trial is supposed to test members from all sorts of populations."
    סטפן בנקל מנכ"ל חברת מודרנהסטפן בנקל מנכ"ל חברת מודרנה
    Moderna CEO Stéphane Bancel meeting with President Donald Trump amd senior U.S. officials at the White House
    (Photo: EPA)
    There is currently no concrete timeline as to when the vaccination will be made available to the general public.
    "We assume that around November-December we will know if the vaccination works," said Zaks.
    "When we will know the vaccine is effective, we will begin administrating it to the public."
    He said that several countries have already bought the vaccine, even before it has been fully tested.
    "Countries are helping us fund the tests, all while making sure they will have access to the vaccination when it is finally ready."
    Melissa Harting receives the shotMelissa Harting receives the shot
    New York nurse Melissa Harting receives a shot during the Moderna phase 3 trial
    (Photo: AP)
    One of the participants in the trial is 36-year-old nurse Melissa Harting.
    "I'm excited to be part of something like this. This is huge," says Harting, who received her injection in Binghamton, New York.
    "Doing our part to eradicate [the virus] is very important to me."
    Talkbacks for this article 0